Sunesis Presents Encouraging Phase II Data for Cancer Drug
Posted on: Tuesday, 11 March 2008, 06:00 CDT
Sunesis Pharmaceuticals has reported positive interim data from the company's ongoing Phase II clinical trial of its lead product candidate, SNS-595, in platinum-resistant ovarian cancer patients.
In this trial, single agent SNS-595 has demonstrated disease control (defined as stable disease, partial response or complete response) in 31 of 35 patients evaluable for best response using Gog-Recist criteria. Of these 31 patients, one patient had a complete response, four patients had partial responses (two unconfirmed) and 26 patients had a best response of stable disease.
All patients enrolled in the trial have previously failed treatment with platinum-containing regimens, and fourteen of the 35 patients have also failed prior treatment with doxorubicin HCl liposome injection (Doxil). Both platinum-resistant and Doxil-resistant patients in the Phase II clinical trial have responded to SNS-595 therapy. Among 45 patients with sufficient follow-up to yield safety data, SNS-595 was generally well tolerated at a dose level of 48mg/m2 administered once every three weeks.
Source: Datamonitor
Related Articles
- Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer
- Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
- Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
- Gentium Announces the Data Safety Monitoring Board Review of the Phase III Trial of Defibrotide to Treat Patients With Severe Veno-Occlusive Disease
- NEJM Owes Patients Responsible Journalism, Says Lyme Disease Association
- Pharmaxis Enrolls Patients for COPD Trial
- Threshold Starts Trial for Platinum-Resistant Cancer Patients
- Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Platinum-Resistant Ovarian Cancer
- Genzyme Begins Trial of Myozyme(R) for Patients With Late-Onset Pompe Disease
- Orlistat Augments Postprandial Increases in Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Damci Et Al./ Orlistat Augments Postprandial Increases In Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Horowitz Et
 |
 |
User Comments (0)
RSS Feeds